Xeris Biopharma Holdings
XERS
36 hedge funds and large institutions have $185M invested in Xeris Biopharma Holdings in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 14 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
20% more funds holding
Funds holding: 30 → 36 (+6)
2.15% more ownership
Funds ownership: 48.45% → 50.6% (+2.1%)
0% more capital invested
Capital invested by funds: $184M → $185M (+$805K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.4M |
| 2 |
BlackRock
New York
|
+$8.02M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.99M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.59M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.41M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.75M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.03M |
| 4 |
Neuberger Berman Group
New York
|
-$2.18M |
| 5 |
Millennium Management
New York
|
-$1.9M |
XERS Hedge Fund Activity: Q3 2018 in Review
36 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2018, worth a combined $185M — up 0.44% from $184M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XERS positions and 14 closed out — a net gain of 6 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $22.4M. The largest seller was Perceptive Advisors, cutting an estimated $5.41M.
- 36 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2018, up from 30 in Q2 2018.
- Funds reported $185M of Xeris Biopharma Holdings stock for Q3 2018, up 0.44% quarter-over-quarter.
- 20 funds opened new Xeris Biopharma Holdings positions in Q3 2018 and 14 closed out, a net change of +6 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2018 was Fidelity Investments, an estimated $22.4M added.
- The largest Xeris Biopharma Holdings seller in Q3 2018 was Perceptive Advisors, an estimated $5.41M sold.
Based on aggregated 13F filings for Q3 2018.